A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

The lawsuits come amid several recent studies showing a link between vision complications and people taking drugs ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Steve Christo – Corbis/Getty Images Semaglutide is a GLP-1 agonist medication that can assist with diabetes management and weight loss ... had better outcomes from non-invasive testing as ...